Abstract
The article discusses analysis of examinations and treatment results 100 children with hemangiomas different localizations on the different stages of existence. The study included patients of different ages, from birth to 6 years. Importance of primary assessment of severity and activity of hemangioma`s, for the choice of treatment, was considered. Correlation between clinical course of hemangiomas and soluble Fas/FasL was analyzed. The object of the research: Clinical course of hemangiomas of different morphological types, soluble form of Fas and FasL in the serum of patients with hemangiomas. Investigated problem: Improving the results of treatment of hemangiomas in children. The main scientific results: Predicting the course of hemangiomas in children allows to determine the need for treatment at different stages of their existence, as well as to carry out timely correction of the prescribed treatment to achieve good cosmetic and functional results. The area of practical use of the research results: Department of Pediatrics, Pediatric Surgery, Dermatology. Innovative technological product: Defined characteristics will help in predicting the course of hemangiomas and the effectiveness of their treatment. Scope of the innovative technological product: Clinical pediatric practice.
Highlights
The object of research This study aims to examine the clinical course and results of treatment of hemangiomas of different morphological types and their relationship with the content of sFas and soluble form of FasL (sFasL) in the serum of patients with hemangiomas. 1
It can be noted that in both gender groups the largest number of hemangiomas in the maximum size was in the range (1.1–5.0) cm
It was found that the average value of sFas in the corresponding age group of Innovative technologies in healthcare children is (11.1±1.3) ng/ml, and sFasL – (2.6±0.5) ng/ml
Summary
The object of research This study aims to examine the clinical course and results of treatment of hemangiomas of different morphological types and their relationship with the content of sFas and sFasL in the serum of patients with hemangiomas. Problem description Infantile hemangiomas (IH) are the most common benign tumor in infants and occur in 5–10 % of children [1]. According to the classification of the International Association for the Study of Vascular Anomalies (ISSVA) 2018, hemangiomas are benign vascular tumors and include IH, as well as congenital hemangiomas (rapid-involving, partially involute, non-involute) [2]. The degree of growth activity during the first year of life is impossible to predict, as it is individual in each case. Some authors believe that active proliferation can last up to 8–12 months, and the regression phase – up to 5–10 years of life [5, 6]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
